CoChat

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Open access
Nan, Xueli, Xie, Chao, Yu, Xueyan, Liu, Jie · 2017 · Oncotarget
Cited by 190

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

// Xueli Nan 1, 2 , Chao Xie 2 , Xueyan Yu 3 and Jie Liu 2, 4 1 School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences, Shandong, China 2 Department of Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong, China 3 Department of Oncology, Shandong Provincial Chest Hospital, Shandong, China 4 Shandong Academy of Medical Sciences, Shandong, China Correspondence to: Jie Liu, email: lj1260814@126.com Keywords: EGFR TKI, first-line treatment, non-small-cell-lung cancer, EGFR mutations, combined therapy Received: February 21, 2017 Accepted: July 26, 2017 Published: August 09, 2017 ABSTRACT After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring EGFR mutations. Besides, combination strategies based on EGFR TKIs in the first line treatment have also been proved to delay the occurrence of resistance. In this review, we summarize the scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the application of monotherapy and combination therapies of the EGFR-based targeted therapy with other agents such as chemotherapy, anti-angiogenic drugs and immunecheckpoint inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.20095

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 190

Metadata

Authors
Nan, X., Xie, C., Yu, X., & Liu, J.
Venue
Oncotarget
Published
2017-08-09
Volume
8
Issue
43
Pages
75712-75726
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2743559198
Cited by
190
References
38
FWCI
10.12
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. https://app.cochat.ai/papers/10.18632/oncotarget.20095
The paper
Nan, X., Xie, C., Yu, X., & Liu, J. (2017). EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.20095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.